Meeting
2021 ASCO Annual Meeting
Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database.
Authors
Vidya Kollu
Gundersen Health System, Lacrosse, WI
Vidya Kollu , Kohei Osterloth , Andrew J. Borgert , Susan M. Frankki , Benjamin Marshall Parsons
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 545)
DOI
10.1200/JCO.2021.39.15_suppl.545
Abstract #
545
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
First Author: Nusayba Ali Bagegni
Poster
2021 ASCO Annual Meeting
Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice.
First Author: Xiaoliang Wang
Poster
2021 ASCO Annual Meeting
Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes.
First Author: Grace Wei
Poster
2020 ASCO Virtual Scientific Program
Value of clinical treatment score post-5 years (CTS5) for late relapse risk assessment in patients with early-stage HER2+ breast cancer (BC) in the north central cancer treatment group (NCCTG) N9831 (Alliance) trial.
First Author: Tanmayi Pai